NCT04082572View on ClinicalTrials.gov

Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2019

Primary Completion Date

November 8, 2024

Study Completion Date

November 8, 2024

Conditions

Locally Advanced Malignant Solid Neoplasm

Interventions

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT04082572 - Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers | Biotech Hunter | Biotech Hunter